[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2134953T3 - Capsulas de gelatina que contienen una solucion de acetaminofeno altamente concentrada. - Google Patents

Capsulas de gelatina que contienen una solucion de acetaminofeno altamente concentrada.

Info

Publication number
ES2134953T3
ES2134953T3 ES94926475T ES94926475T ES2134953T3 ES 2134953 T3 ES2134953 T3 ES 2134953T3 ES 94926475 T ES94926475 T ES 94926475T ES 94926475 T ES94926475 T ES 94926475T ES 2134953 T3 ES2134953 T3 ES 2134953T3
Authority
ES
Spain
Prior art keywords
highly concentrated
soft gel
gelatin capsules
capsules containing
acetaminophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926475T
Other languages
English (en)
Inventor
Rickey S Shelley
Youching Wei
Deborah Linking
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Pharma Solutions Inc
Original Assignee
Catalent Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134953(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Catalent Pharma Solutions Inc filed Critical Catalent Pharma Solutions Inc
Application granted granted Critical
Publication of ES2134953T3 publication Critical patent/ES2134953T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN METODO PARA AUMENTAR LA SOLUBILIDAD DE ACETAMINOFENO SOLO O EN COMBINACION CON ANTIHISTAMINICOS, ANTITUSIVOS, DESCONGESTIONANTES Y EXPECTORANTES PARA FORMAR UNA SOLUCION CLARA DE ENCAPSULACION EN UN GEL BLANDO. EL ACETAMINOFENO SE SOLUBILIZA SOLO O EN COMBINACION CON LOS INGREDIENTES ANTERIORES MEDIANTE LA MEZCLA CON GLICOL DE POLIETILENO, GLICOL DE PROPILENO, AGUA, POLIVINILPIRROLIDENO Y ACETATO DE POTASIO (O DE SODIO). ESTA INVENCION AUMENTA LA SOLUBILIDAD DEL ACETAMINOFENO PARA OBTENER EL MISMO TAMAÑO DE GEL BLANDO PARA UNA DOSIS DE 325 MG MIENTRAS QUE ACTUALMENTE ESTA DISPONIBLE PARA UN PRODUCTO DE GEL BLANDO DE 250 MG DE DOSIS. EL SISTEMA DE DISOLVENTE DESCRITO ES UTIL PORQUE PROPORCIONA UNA SOLUCION ALTAMENTE CONCENTRADA DE ACETAMINOFENO CAPAZ DE ENCAPSULACION EN UNA CAPSULA LO SUFICIENTEMENTE PEQUEÑA PARA PERMITIR UN FACIL TRAGADO.
ES94926475T 1993-08-05 1994-08-04 Capsulas de gelatina que contienen una solucion de acetaminofeno altamente concentrada. Expired - Lifetime ES2134953T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10246493A 1993-08-05 1993-08-05
US08/263,630 US5505961A (en) 1993-08-05 1994-06-22 Gelatin capsules containing a highly concentrated acetaminophen solution

Publications (1)

Publication Number Publication Date
ES2134953T3 true ES2134953T3 (es) 1999-10-16

Family

ID=26799397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926475T Expired - Lifetime ES2134953T3 (es) 1993-08-05 1994-08-04 Capsulas de gelatina que contienen una solucion de acetaminofeno altamente concentrada.

Country Status (10)

Country Link
US (1) US5505961A (es)
EP (1) EP0713390B1 (es)
JP (1) JP3678745B2 (es)
KR (1) KR100341522B1 (es)
AU (1) AU701771B2 (es)
BR (1) BR9407178A (es)
CA (1) CA2168732C (es)
DE (1) DE69419019T2 (es)
ES (1) ES2134953T3 (es)
WO (1) WO1995004527A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435104D1 (de) * 1993-09-28 2008-07-31 Scherer Gmbh R P Herstellung von Weichgelatinekapseln
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5510389A (en) * 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5660859A (en) * 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5770215A (en) * 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
KR100578669B1 (ko) * 1997-05-29 2006-12-07 동아제약주식회사 우르소데옥시콜린산을함유하는투명연질캅셀
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
KR100610403B1 (ko) * 1998-01-20 2006-08-10 어플라이드 애널리티컬 인더스트리즈, 인크. 경구용 액상 또는 반-고체 조성물을 포함하는 약제학적 조성물 및 이의 제조방법
US6846495B2 (en) * 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US6383515B2 (en) 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
IT1313579B1 (it) * 1999-07-30 2002-09-09 Acraf Composizione farmaceutica liquida a base di paracetamolo.
US20030034458A1 (en) * 2001-03-30 2003-02-20 Fuji Photo Film Co., Ltd. Radiation image storage panel
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US7029698B2 (en) * 2001-11-21 2006-04-18 R.P. Scherer Technologies, Inc. Acetaminophen compositions
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
US8231896B2 (en) * 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US8333989B2 (en) * 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
CN100364521C (zh) * 2005-12-22 2008-01-30 浙江万联药业有限公司 含对乙酰氨基酚的软胶囊组合物
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
JP2011510005A (ja) 2008-01-18 2011-03-31 ダウ グローバル テクノロジーズ インコーポレイティド メトキシポリエチレングリコールを用いる難溶性活性物質の水溶解度増強方法
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
US8518438B2 (en) * 2011-01-14 2013-08-27 Enspire Group, Llc Highly concentrated liquid acetaminophen solutions
US8969416B2 (en) * 2012-03-29 2015-03-03 Enspire Group LLC Polyvinylpyrrolidone-containing acetaminophen liquid formulations
ES2792082T3 (es) 2013-02-28 2020-11-10 Pf Consumer Healthcare 1 Llc Estabilidad mejorada de composiciones líquidas novedosas
SG11201507369WA (en) * 2013-03-15 2015-10-29 Novartis Consumer Health Inc Dye free liquid therapeutic solution
WO2014149939A1 (en) * 2013-03-15 2014-09-25 Novartis Consumer Health Inc. Dye free liquid therapeutic solution
WO2016084099A1 (en) * 2014-11-25 2016-06-02 Biological E Limited Soft gelatin capsule composition of anti-tussive agents
AU2016251535B2 (en) 2015-04-23 2021-02-04 Basf Se Gel capsule containing sterol and solubilising agent
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
KR102050069B1 (ko) * 2019-03-29 2019-11-28 (주)알피바이오 안정성이 향상된 연질캡슐 제제용 충진조성물 및 이를 포함하는 연질캡슐 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956490A (en) * 1972-05-22 1976-05-11 Interx Research Corporation Administration of alkaline earth metal salts of salicylamide
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation

Also Published As

Publication number Publication date
AU701771B2 (en) 1999-02-04
CA2168732A1 (en) 1995-02-16
CA2168732C (en) 1999-10-12
DE69419019D1 (de) 1999-07-15
EP0713390A1 (en) 1996-05-29
BR9407178A (pt) 1996-09-17
DE69419019T2 (de) 1999-11-11
KR100341522B1 (ko) 2002-11-23
JP3678745B2 (ja) 2005-08-03
WO1995004527A1 (en) 1995-02-16
US5505961A (en) 1996-04-09
KR960703576A (ko) 1996-08-31
AU7629994A (en) 1995-02-28
JPH09503495A (ja) 1997-04-08
EP0713390B1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
ES2134953T3 (es) Capsulas de gelatina que contienen una solucion de acetaminofeno altamente concentrada.
US5912011A (en) Solvent system to be enclosed in capsules
EP0121321A3 (en) Pharmaceutical compositions
US5141961A (en) Process for solubilizing difficulty soluble pharmaceutical actives
US5641512A (en) Soft gelatin capsule compositions
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
JPH08507494A (ja) 強化溶解度の製薬溶液
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ES2035821T3 (es) Sistema de administracion enterica dirigida.
AU6770490A (en) Solid pharmaceutical compositions containing cimetidine
MY102459A (en) Oral sustained release pharmaceutical preparation.
KR970005285A (ko) 페노피브레이트의 새로운 약학적 적량 처방 및 적용
KR960021032A (ko) 연성 젤라틴 약제학적 용량형
NZ514323A (en) A immunostimulant containing an acitive agent and an adjuvant which increases the effect of the active agent
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
AU547175B2 (en) Stabilised prostaglandin formulations
KR840003415A (ko) 경구용 당뇨병 치료제의 제조방법
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
JPS56140924A (en) Calcitonin pharmaceutical preparation
AR016629A1 (es) Una solucion que comprende un azaesteroide farmaceuticamente activo y un ester de acido graso de glicerol o propilen glicol, composiciones farmaceuticasque comprenden la solucion y capsulas de gelatina rellenas con la composicion farmaceutica.
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
JP2005514367A (ja) アセトアミノフェン組成物
ES2127305T3 (es) Una forma farmaceutica para la administracion rectal de compuestos farmacologicamente activos.
JPS577422A (en) Crocosmia aurea "plach"
MXPA01001490A (es) Acido acetilsalicilico entregado transdermalmente.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 713390

Country of ref document: ES